SAT0250 Cardiovascular Risk Predictors under Non-Tnf Biological DMARD Treatment. A 12-Month Longitudinal Study. (10th June 2014)

• Record Type: Journal Article
• Authors: Provan, S.A.; Berg, I.J.; Semb, A.G.; Mathiessen, A.; Hammer, H.B.; Kvien, T.K.
• Is Part Of: Annals of the rheumatic diseases. Volume 73:Supplement 2(2014)
• Page Start: 683
• Page End: 683
• Publication Date: 2014-06-10
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2014-eular.3409
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: Patients with rheumatoid arthritis (RA) have an increased level of cardiovascular (CV) risk markers. Objectives: To assess whether treatment with one of three biological DMARDs; Rituximab (Rit), Abatacept (Aba) or Tocilizumab (Toc) can reduce the level of CV risk markers in patients with RA. Methods: An open, observational, longitudinal study with study visits at baseline, 3, 6, and 12 months. Patients aged 18-80 years, fulfilling the ACR 1987 classification criteria for RA and starting on either Rit, Aba or Toc based on the decision of a rheumatologist, were included. CV risk was assessed by blood pressure and arterial stiffness measurements (pulse wave velocity (PWV) and augmentation index (AIx)). Change in CVD risk markers over 3 months were compared using paired samples bivariate tests. Change over the 12 months follow-up in patients receiving Rit was assessed using mixed models repeated analyses. Results: 36 patients were included in the study and 4 patients were re-entered into the study after switching to either Toc or Aba prior to the 6 month follow-up. The final number included was 40, 24 patients receiving Rit, 5 Aba and 7 Toc. In the bivariate analyses of paired samples at 3 months DAS28 was significantly improved in the Rit and Toc groups. Only patients receiving Toc had a significant reduction in CRP, ESR and PWV at 3 months (Table 1 ). Over the 12-month follow-up period patients in the Rit group showed a significant reduction in CRP, DAS28 and PWV (Fig. 1 ). Conclusions: Toc and Rit reduce PWV, a marker of CVD risk, in patients with RA. The reduction in PWV was apparent at 3 months for patients taking Toc and at 12 months for patients receiving Rit. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2014-eular.3409